neuropilin-1(nrp1)

EG01377 2HCl is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1) with a Kd value of 1.32 μM and an IC50 value of 609 nM for both EG01377 2HCl against NRP1-a1 and NRP1-b1.EG01377 exhibits anti-angiogenic, antimigratory and antitumor activities.

Vesencumab (MNRP-1685A) is an IG1 antibody targeting NRP-1 with anti-angiogenic and anti-tumor activity that reduces the number of globules formed by the SUM159 and Hs578T cell lines. Vesencumab inhibits EGFR and PDGFRα activation and can be used to study solid tumors.

EG00229 is a neuropilin 1 (NRP1) receptor antagonist that selectively inhibits the binding of VEGF-A to the NRP1 b1 domain with an IC50 value of 3 μM. It does not affect the binding of VEGF-A to other receptors, such as VEGFR-1 and VEGFR-2.

EG01377 has antiangiogenic, antimigratory, and antitumor effects.EG01377 is a neuropilin-1 (NRP1) antagonist, with a Kd of 1.32 μM for NRP1-b1, and IC50s of both 609 nM for NRP1-a1 and NRP1-b1, but shows no effect on NRP2.

EG01377 dihydrochloride is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1) , with a K d of 1.32 μM, and IC 50 s of 609 nM for both NRP1-a1 and NRP1-b1 . EG01377 dihydrochloride has antiangiogenic, antimigratory, and antitumor effects .